CardioMetabolIQ

Its All Connected. Every aspect of liver, metabolic and cardiovascular physiology affects every other. To see the risks, and most importantly, the steps to reduce risks, one must look carefully at the Big Picture. That is CardioMetabolIQ’s mission.

By integrating key markers for liver function and fat content, cardio- and cerebrovascular health, and multi-faceted metabolic function, the dried blood spot CardioMetaboliQ test provides a level of utility, scope and value to the user that is first in class.
 
Most blood panels include liver function markers ALT and AST. These markers are actually not optimal in assessing Fatty Liver. Kotronen A et al, (2009)* demonstrated that as many as 80% of subjects with Fatty Liver were not properly identified using ALT in assessment. 
 
The Fatty Liver Index used in the CardioMetaboliQ test has been the gold standard for non-invasive Fatty Liver assessment since it was introduced in 2006. Because Fatty Liver significantly worsens cardiovascular, metabolic and many other diseases, getting timely, accurate assessment is vital.
 
Clarity is critical. CardioMetaboliQ keeps that in mind with the CardioMetaboliQ Index, a single risk-averaged composite score that combines 10 critical markers from the Health Report. 
 
Because liver, metabolic, and cardiovascular factors are all involved in cardiometabolic health, we provide a single data point that reflects an aggregate relative risk across the entire cardiometabolic health spectrum.
 
We know that receiving your test results is just the beginning. At CardioMetaboliQ we focus on giving users the tools for what comes after testing. Our BioCalculator and Research sections provide excellent tools for following through, for next steps.